The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris

Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02198-19. doi: 10.1128/AAC.02198-19. Print 2020 Feb 21.

Abstract

The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).

Keywords: Candida auris; T-2307; caspofungin; fluconazole; in vitro susceptibility; invasive candidiasis; murine model.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Amidines / therapeutic use*
  • Animals
  • Antifungal Agents / therapeutic use*
  • Candida / drug effects
  • Candida / pathogenicity*
  • Candidiasis, Invasive / drug therapy*
  • Caspofungin / therapeutic use
  • Disease Models, Animal
  • Drug Resistance, Fungal
  • Fluconazole / therapeutic use
  • Male
  • Mice
  • Mice, Inbred ICR

Substances

  • Amidines
  • Antifungal Agents
  • T-2307
  • Fluconazole
  • Caspofungin